Previous 10 | Next 10 |
2023-12-12 08:39:32 ET Losers: Achieve Life Sciences ( ACHV ) -24% announces participation at upcoming investor conferences. Clearmind Medicine CMND -13% files for $50M mixed shelf . Oracle Corp. ORCL -10% after Q2 earnings release . Acurx Pharmaceu...
2023-12-11 16:53:07 ET DENVER, Colo., Dec. 11, 2023 ( www.247marketnews.com )- 24/7 Market News covered the following companies today; Marker Therapeutics, Inc. (NASDAQ: MRKR), Poseida Therapeutics (NASDAQ: PSTX), Assure Holdings (NASDAQ: IONM), Jet AI (NASDAQ: JTAI), and NextPlay Techn...
2023-12-11 12:51:49 ET Gainers: Jet.AI ( JTAI ) +70% . Boqii Holding Limited ( BQ ) +34% . Marker Therapeutics ( MRKR ) +34% . Morphosys AG ( MOR ) +25% . G1 Therapeutics ( GTHX ) +24% . Innoviz Technologies Ltd ( INVZ ) ...
2023-12-11 12:16:39 ET DENVER, Colo., Dec. 11, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Pasithea Therapeutics Corp (NASDAQ: KTTA), Marker Therapeutics Inc (NASDAQ: MRKR), Macy’s Inc (...
HOUSTON, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today reported a clinical ...
2023-11-10 11:12:12 ET More on Marker Therapeutics Marker gains as lymphoma therapy leads to complete remission Financial information for Marker Therapeutics For further details see: Marker Therapeutics GAAP EPS of -$0.34, revenue of $257.61M
Announced complete response in first patient with lymphoma treated with MT-601 in Phase 1 APOLLO trial following CAR T relapse Received Orphan Drug Designation (ODD) from European Medicines Agency (EMA) for multiTAA-specific T cell product candidate MT-401 ( zedenoleucel ) for t...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Marker Therapeutics Inc. (MRKR) is expected to report for Q1 2024
2023-09-11 08:20:32 ET More on Marker Financial information for Marker Therapeutics For further details see: Marker gains as lymphoma therapy leads to complete remission
News, Short Squeeze, Breakout and More Instantly...
Marker Therapeutics Inc. Company Name:
MRKR Stock Symbol:
NASDAQ Market:
Marker Therapeutics Inc. Website:
Preliminary data from study in patients with lymphoma enrolled at City of Hope National Medical Center was presented at the 11th Global Summit on ...
Preliminary data from study in patients with lymphoma enrolled at City of Hope National Medical Center was presented at the 11 th Global Summit on Hematologic Malignancies in Whistler, BC, Canada Study participants tolerated initial dose level well and demonstrated durab...
Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...